An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (CEX) as primary treatment for large operable or locally advanced/inflammatory breast cancer
Nom du journal : Eur J Cancer
Année : 2003
Volume : 39
Page de départ : 1277
Page de fin : 1283